Artiva Biotherapeutics, Inc. (ARTV) stock
ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.96−0.05 (-1.25%)
Close on Nov 16, 2026Market cap $193.61MP/E –Yield –
Artiva Biotherapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Artiva Biotherapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$93.46M. For fiscal 2025 it was -$87.21M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$87.21M | – |
| FY2024 | Dec 31, 2024 | -$64.85M | – |
| FY2023 | Dec 31, 2023 | -$28.41M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$26.20M | – |
| Q1 FY2026 | Mar 31, 2026 | -$23.76M | – |
| Q4 FY2025 | Dec 31, 2025 | -$21.27M | – |
| Q3 FY2025 | Sep 30, 2025 | -$22.24M | – |
| Q2 FY2025 | Jun 30, 2025 | -$22.17M | – |
| Q1 FY2025 | Mar 31, 2025 | -$21.54M | – |
| Q4 FY2024 | Dec 31, 2024 | -$17.65M | – |
| Q3 FY2024 | Sep 30, 2024 | -$17.71M | -255.8% |
| Q2 FY2024 | Jun 30, 2024 | -$15.59M | – |
| Q1 FY2024 | Mar 31, 2024 | -$13.91M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.38M | – |
| Q3 FY2023 | Sep 30, 2023 | $11.37M | – |
See a number that looks wrong?